and, if required, in the evening. 1 However, this conventional dosage scheme has been demonstrated to expose patients to supraphysiological levels of cortisol. 3 Overexposure to GCs has been demonstrated to increase metabolic dysfunction, hypertension, sleep pattern disturbance and cardiometabolic risk, resulting in impaired quality of life and enhancing mortality and morbidity. 3, 4 Few studies have been conducted aiming to improve health-related outcomes, through a decrease in the daily doses of GCs, only resulting in a weight decrease, without any favourable effects on hypertension and/or glucose metabolism. 5 However, a quite recent study demonstrated that higher doses of hydrocortisone are associated with a better health-related quality of life than lower ones. 6 Recently, a novel once-daily dual-release HC (DR-HC) was approved for treatment of AI in adults, characterized by an immediaterelease fraction of HC in the outer layer of the tablet and an extended-release fraction in the core, able to provide an adequate concentration of cortisol within 50 minutes after administration, half cortisol plasmatic concentration for 6 hours thereafter and a minimal cortisol level 18-24 hours after intake. 7 This formulation tends to provide a cortisol exposure-time profile close to the physiological one, improving anthropometric parameters, HbA1c and questionnaire-related quality of life and appears to be safe even in the long-term. [8] [9] [10] [11] [12] The aim of this study was to evaluate the effects of DR-HC (Plenadren, Shire Italy) in patients with normal glucose tolerance (NGT) and prediabetes (impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT] ), on anthropometric parameters, insulin sensitivity and secretion and cardiometabolic risk indirectly estimated by a surrogate parameter, the visceral adiposity index (VAI), after switching from conventional GC treatment, during a 36-month follow-up.
| MATERIALS AND METHODS

| Study participants
We retrospectively recruited 49 patients, 25 with NGT and 24 with prediabetes, with chronic PAI and SAI, who were on stable GC replacement therapy before entering the study, consecutively referred to the
Division of Endocrinology of Palermo University from January 2012 to
December 2016. All patients had a disease duration of at least 2 years.
Adrenal insufficiency (AI) was diagnosed first assessing the function of adrenal cortex by serum cortisol in the morning. An early morning serum cortisol level lower than 3 μg/dL confirmed AI. Patients with cortisol levels more than 3 μg/dL and high clinical suspicion of AI were further evaluated by the corticotropin stimulation test at the standard dose of 250 μg. A normal response was a plasma cortisol concentration higher than 18 μg/dL at 30 minutes after the injection. Once AI was confirmed, we established the aetiology by measurement of ACTH levels.
In patients with PAI, adrenal antibodies against the steroidogenic enzyme 21-hydroxylase and other autoimmune polyendocrine insufficiencies (thyroid disease, premature ovarian failure, type 1 diabetes mellitus, hypoparathyroidism, candidiasis) were assessed as recently reported by international guidelines. 13 In addition, a computed tomography scanning of adrenal glands was assessed to rule out infectious, haemorrhagic or metastatic causes.
For patients with SAI, magnetic resonance imaging of the pituitary gland was indicated.
Patients with adrenocortical carcinoma, overt diabetes mellitus, polyglandular autoimmune syndrome and pregnancy were excluded from the study.
Overall, 36 patients had SAI, and 13 patients had isolated autoimmune PAI. Twenty patients with SAI had prediabetes (9 with IFG, 6 with IGT and 5 with IFG and IGT, respectively), while 16 had NGT.
Four patients with PAI had prediabetes (2 with IFG and 2 with IGT), while 20 had NGT.
Among patients with SAI, 5 had an isolated disease, 3 had com- With regard to patients with prediabetes, no lifestyle changes or any drugs were suggested, to avoid any interference with glucose metabolism.
During the 36-month treatment, the DR-HC dose was changed based on the physician's judgement of a patient's need in both groups of patients (Table 1) . Treatment with fludrocortisone was not changed during the study.
The study was carried out in accordance with the recommendations of the Policlinico Paolo Giaccone Ethics Committee, with written informed consent from all subjects, in accordance with the Declaration of Helsinki.
| Study design
At baseline and after 12, 24 and 36 months of DR-HC treatment, patients underwent a complete clinical and metabolic evaluation, including a detailed assessment of insulin secretion and sensitivity. To evaluate the differences between patients with NGT and prediabetes during the 36 months of treatment with DR-HC, the change from baseline to 36 months of therapy (Δ value) of all parameters was calculated.
In addition, a comparison was made between patients, according to the aetiology of AI (PAI and SAI).
| Assays
Insulin, glycaemia, HbA1c and lipids were measured by standard methods (Modular P800, Roche, Milan). LDL-C levels were measured 
| Statistical analysis
The Statistical Packages for Social Science SPSS version 19 (SPSS, Inc., IBM, New York, USA) was used for data analysis. The normality of quantitative variables was tested with the Shapiro-Wilk test.
Baseline characteristics of the groups were presented as mean ± SD for continuous variables, while rates and proportions were calculated for categorical data. The comparison between numerical variables at baseline, 12-, 24-and 36-month follow-up was performed with the Friedman analysis and chi-square for trend for categorical variables both in the total group and in the single groups (NGT and prediabetes and PAI and SAI). A P value <.05 was considered statistically significant.
| RESULTS
Patients with SAI were on stable control for the other pituitary insufficiencies during the 36 months of treatment. At baseline and after 36 months of DR-HC, respectively, they had IGF-1 levels 168.5 ± 45.4 and 178.5 ± 39.6 ng/mL, FT4 levels 1.47 ± 0.30 and 1.39 ± 0.32 ng/dL, total testosterone 5.4 ± 1.8 and 5.6 ± 1.65 ng/dL and total estrogens 98.2 ± 27.6 and 103 ± 30.1 pg/mL.
The effects of the different doses of DR-HC on metabolic parameters were also evaluated in all patients. However, only a minority of patients, 14/49 (28.6%) had their dose changed, and no differences were found with the change in dosage (data not shown).
| Comparison of patients according to glucose tolerance
The baseline characteristics of patients with AI grouped according to glucose tolerance, NGT and prediabetes are shown in Table 2 .
At baseline, there were no significant differences regarding age, duration of disease, gender, type and dose of oral GC replacement therapy between the two groups (NGT and prediabetes) ( Table 2) . By contrast, patients with prediabetes showed significant differences regarding BMI, WC, HbA1c, AUC 2 h glycaemia, insulinaemia, AUC 2 h insulinaemia , ISI-Matsuda, compared to patients with NGT, as reported in Table 2 .
During the 36 months of DR-HC, in all patients, a significant decrease in BMI (P < .001), WC (P < .001) and HbA1c (P < .001) was observed. No significant differences were found for the other parameters (results not shown).
By contrast, in patients with NGT and prediabetes, a significant decrease in BMI (P = .017 and P < .001), WC (P = .008 and P < .001), HbA1c
(P = .034 and P = .001) and a significant increase in HDL-C (P = .036 and P = .043) were, respectively, observed during the 36 months of DR-HC ( Figure 1 ). In addition, in prediabetic patients, only we found a significant decrease in insulinaemia (P = .014), AUC 2 h insulinaemia (P = .038) and the VAI (P = .001), in concomitant with a significant increase in DIo (P = .041) and ISI-Matsuda (P = .038) (Figures 1 and 2 ).
Comparing the Δ value from baseline to 36 months between patients with NGT and prediabetes, a significant decrease of Δ BMI (P = .009),
Δ insulinaemia (P = .008), Δ AUC 2 h insulinaemia (P = .011) and Δ ISI-Matsuda (P = .040)
was observed in patients with prediabetes. 
| Comparison of patients according to adrenal insufficiency aetiology
During the 36 months of DR-HC, no differences in electrolytes, clinical and metabolic parameters and insulin secretion and sensitivity indexes were found comparing patients with PAI and SAI (results not shown).
| DISCUSSION
The current study demonstrates that 36-month therapy with DR-HC is associated with an improvement of anthropometric and metabolic parameters and cardiometabolic risk, evaluated by a surrogate parameter, the VAI, in patients both with NGT and prediabetes.
However, patients with prediabetes appear to have a stronger improvement of insulin secretion and sensitivity compared to those with NGT.
T A B L E 2 Baseline clinical and phenotypic features of patients grouped according to glucose tolerance in patients with normal glucose tolerance (NGT) and prediabetes
Patients with NGT N = 25
Patients with prediabetes N = 24 P Subjects (%) Subjects (%) Decreased insulin sensitivity and impaired pancreatic β-cell function are the two key components in the pathogenesis of type 2 diabetes mellitus. Therefore, assessment of insulin sensitivity and secretion in patients with AI potentially at risk of glucose metabolism impairment, as during GC replacement treatment, is of crucial importance.
As several studies have reported, cortisol plays an important role in glucose and insulin metabolism and an excess of substitutive GC therapy can have detrimental implications for glucose homoeostasis. 1 However, data on the effects of DR-HC treatment on insulin secretion and sensitivity in AI are still lacking.
In healthy subjects, physiological levels of cortisol fluctuate from a peak of 136-720 nmol/L in the morning to 50-331 nmol/L in the night. 17 Conventional GCs are administered twice-three times daily with the highest dose in the morning and a lower dose in the afternoon. These dosing regimens are designed to avoid overtreatment during the night-time nadir of physiological cortisol secretion and to reflect the peak release of cortisol at the time of waking. 1 In stressful situations, such as high body temperature, trauma, surgery and during any intercurrent illness, the GC dose should be increased to maintain adequate cortisol levels.
Many studies have shown that conventional GC replacement therapy is associated with reduced life expectancy and increased morbidity in patients with AI, compared to the general population. 18, 19 In a recent survey on 1281 participants, conventional GC treatment was demonstrated to be associated with impaired quality of life, fatigue, high absenteeism from work or school and a high rate of hospitalization for adrenal crises, vomiting or acute infections. 20 All of these GC treatment drawbacks are thought to be due to lack of adequate F I G U R E 1 Changes in metabolic parameters during 36 mo of dual-release hydrocortisone (DR-HC) treatment in patients with adrenal insufficiency (AI)-normal glucose tolerance (NGT) (dark grey line) and prediabetes (light grey line). For trend: *P < .05, **P < .01; ***P < .001. NS, not significant patient education and failure to individualize the dose, leading mainly to overexposure, inability to achieve a near-physiological diurnal profile of cortisol exposure and failure to provide adequate treatment in response to stress. In a fairly recent Swedish multicentre study comparing conventional hydrocortisone and DR-HC in 64 patients with primary AI, a significant reduction of weight, systolic and diastolic blood pressure and improvement of HbA1c, especially in patients with diabetes mellitus, was observed during DR-HC treatment. 10 In addition, in a prospective study on 50 patients with PAI and SAI and congenital adrenal hyperplasia, a significant reduction of BMI and HbA1c was observed in patients treated with DR-HC, compared with patients on conventional GC treatment.
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A subsequent study, evaluating the switch from conventional HC to DR-HC in 19 patients with AI, showed a significant reduction of WC, HbA1c and LDL cholesterol after 12 months of DR-HC therapy. 12 By contrast, in a Swedish 5-year study on 71 patients with PAI treated with DR-HC, an increase in fasting glucose and HDL-C was observed, 22 without any change in anthropometric parameters.
In agreement with previous studies, we found a decrease in BMI, WC and HbA1c and an increase in HDL-C in all patients treated with DR-HC.
As expected, patients with prediabetes had higher baseline AUC 2 h glycaemia , insulinaemia, AUC 2 h insulinaemia and lower ISI-Matsuda, than patients with NGT. In the group of patients with prediabetes, we also found a significant improvement in insulin secretion and sensitivity, which to our knowledge has not been investigated previously.
Treatment with conventional GCs is known to affect glucose metabolism, inducing peripheral insulin resistance by impairing insulin signalling, resulting in decreased glucose disposal and increased glucose production. 23 In response to GC-induced peripheral insulin resistance and trying to maintain normoglycaemia, β-pancreatic cells undergo several adaptations resulting in hyperinsulinaemia. 24 Patients receiving long-term GC replacement therapy develop abnormal glucose tolerance more frequently than healthy individuals, 1 due to supraphysiological GC exposure in the early evening, which has asymptomatic but adverse metabolic effects. 25 In a study evaluating the effect of acute and chronic low doses of prednisolone in patients with rheumatoid arthritis, insulin sensitivity worsening and postprandial glucose increase were observed. 26 As expected, higher insulin requirement was shown in a study conducted on patients with type 1 diabetes mellitus and PAI, compared to patients with type 1 diabetes mellitus alone.
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F I G U R E 2 Changes in insulin sensitivity and secretion parameters during 36 mo of dual-release hydrocortisone (DR-HC) treatment in patients with adrenal insufficiency (AI)-normal glucose tolerance (NGT) (dark grey line) and prediabetes (light grey line). For trend: *P < .05, **P < .01; ***P < .001. NS, not significant
In the current study, the improvement in insulin secretion in patients with prediabetes is demonstrated by the reduction of insulinaemia and the increase in insulin secretion relative to insulin resistance (DIo). Indeed, DIo, which expresses the ability of β-cells to adequately compensate insulin resistance through increased insulin secretion, is a predictable factor of diabetes development in adults, 15 and for this reason, it may be useful to evaluate this risk related to overtreatment with GC in AI patients.
On the other hand, ISI-Matsuda is a useful tool to evaluate the insulin resistance degree of the whole body. It derives from OGTT and more closely correlates with the M-value of the euglycaemic hyperinsulinaemic clamp, which represents the gold standard of insulin sensitivity measurement. 14 The increase in ISI-Matsuda during the 36 months of DR-HC in patients with prediabetes clearly shows an improvement in insulin sensitivity.
Interestingly, the variation of the daily oral HC dose was not demonstrated to affect insulin sensitivity and/or secretion, 27 while the change in the scheme of administration provided discordant results.
In a Norwegian study evaluating an HC infusion pump system, able to mime the physiological cortisol profile, used for 3 months in 7 patients with AI, reestablishment of the cortisol circadian rhythm and an improvement of quality of life 28 were observed. Conversely, another study conducted on 15 patients with SAI, receiving either a low dose of oral HC replacement therapy or a physiological hydrocortisone infusion, did not demonstrate any change in insulin sensitivity. 29 The term cardiometabolic risk was coined by the American Diabetes Association 30 and the American Heart Association 31 to describe the overall risk of developing type 2 diabetes and cardiovascular disease.
To predict visceral adipose tissue-associated cardiometabolic risk, the VAI has been demonstrated to be a useful tool. 13 Visceral fat is universally claimed to be more strongly associated with cardiometabolic risk than subcutaneous fat, 32 due to its endocrine function. The VAI has been shown to correlate well with the adipokine profile in patients with type 2 diabetes 33 and to provide a good estimate of visceral adipose dysfunction, reflecting the cardiometabolic risk in many diseases. 34 In the current study, 36-month treatment with DR-HC in patients with prediabetes was associated with a significant improvement of cardiometabolic risk, indirectly estimated by the VAI. In addition, after 36 months of DR-HC, the VAI tended to be <2, the cut-off to identify patients without visceral adipose dysfunction. However, all patients enrolled in the study were on stable replacement treatment and maintained a good and stable hormonal control during the whole follow-up, so not affecting, in our opinion, the outcomes of the study.
Despite these limitations, we think that the strength of the study is that it represents the first study assessing insulin sensitivity and secretion and a surrogate index of cardiometabolic risk in patients with PAI and SAI treated with DR-HC.
In conclusion, long-term DR-HC therapy is associated with an improvement of insulin secretion and sensitivity in patients with prediabetes. However, both patients with NGT and prediabetes appear to benefit from treatment with DR-HC in terms of improvement of visceral adiposity, glycaemic control and HDL-C levels.
Further case-controlled studies performed in a larger cohort of patients are required to verify our preliminary data.
